White House says new order narrows childhood vaccine recommendation from 18 diseases to 11

A presidential action posted on whitehouse.gov at an August 2026 address, titled "Delivering Gold Standard Childhood Vaccine Recommendations for Americans," directs that the combined measles, mumps and rubella vaccine "should be administered in three separate single-disease shots." A White House fact sheet published at a whitehouse.gov address dated the same month describes the new recommendation as covering immunizations "to provide protection for 11 diseases," a figure the fact sheet calls "a decrease from the 18 diseases recommended by the Centers for Disease Control." The signing was by President Donald J. Trump (R), according to CBS News.

On the product the order names, the Center for Infectious Disease Research and Policy at the University of Minnesota (CIDRAP) published an op-ed on the order stating: "There is no measles-only vaccine available in the United States. There is no mumps-only vaccine and no rubella-only vaccine, either."

What the order directs

Beyond the MMR provision, the order states that to the maximum extent feasible childhood immunizations should be given at separate medical visits, and that options should be offered for giving core childhood vaccines as single rather than combination products, beginning with MMR. It also calls for the development of additional alternative adjuvants to aluminum and for comparative safety and efficacy studies. In a section on state law, it directs the Attorney General to "further meritorious legal actions challenging State laws" that the order says conflict with constitutional and federal statutory obligations.

On international comparison, the order and the fact sheet both state that the United States currently recommends more childhood vaccines than any peer nation, and more than twice as many vaccine doses as some European nations. The line that the United States is among a minority of peer nations with childhood vaccine mandates appears in the fact sheet, not in the text of the presidential action reviewed for this piece. Both documents state that most peer nations maintain high childhood vaccination rates through public trust and education rather than mandates.

CIDRAP's op-ed states that the only evidentiary document the order cites is a January 2026 assessment by the Department of Health and Human Services, and characterizes the supporting record as containing no trial, no safety signal and no dataset.

Two counts, measuring different things

The fact sheet puts the 2024 count of recommended routine vaccines at at least 84. Separately, CBS News reported Trump saying at the signing: "In many cases, we were requiring 72 jabs for our beautiful, healthy, lovely, delicate little children." One figure is a written count of recommended routine vaccines; the other is a spoken count of jabs. Neither term is defined in the documents held for this piece, which therefore does not treat the two numbers as the same quantity counted differently.

The record on single-disease shots

Merck once produced monovalent measles, mumps and rubella vaccines. A report published by Infectious Diseases in Children on Healio, at a record dated March 31, 2012, quotes the company: "Merck will not resume production of our monovalent measles, mumps and rubella vaccines." That report states the company's reasoning as follows: "Merck's decision is based on the ACIP's stated general preference for combination vaccines." This piece could not verify Merck's position in 2026; see the method box below.

CIDRAP reports that Merck told PolitiFact that splitting MMR would in effect create three new separately licensed vaccines requiring full clinical testing and regulatory review, and that the company estimated more than 10 years to approval and commercialization. CIDRAP also states that the World Health Organization has prequalified a standalone measles vaccine and a standalone rubella vaccine, and has never prequalified a standalone mumps vaccine anywhere in the world.

On what a split would change, CIDRAP wrote: "Splitting MMR into three single-disease products removes nothing from the total. The tally stays at six. The number of shots goes from two to six."

The response from a Senate physician

Sen. Bill Cassidy (R-La.) said of the order, in remarks reported by HuffPost: "I'm a doctor. This executive order is wrong." He also stated: "Breaking up vaccines will mean children have to get more shots to get the same protection, not fewer shots." In the same statement, Cassidy stated that vaccines are overwhelmingly safe, that they are effective and that they do not cause autism, and said parents should follow their child's pediatrician rather than the order.

CBS News reported Trump saying at the signing that the announcement concerned autism in particular, that children decades ago received a small fraction of the vaccines given today, that the autism rates he described as epidemic did not exist then, and that the administration would move those rates closer to where they had been. CBS News also reported him saying that the cause of autism is not known and that every biologically plausible hypothesis would be examined. Cassidy's statement, quoted above, contradicts the autism link directly.

CIDRAP reported 2,465 confirmed measles cases as of August 6, which it called the highest annual measles total since 1991. CIDRAP also reported national kindergarten coverage of 92.5% in the 2024-25 school year, with individual schools and counties far below that, and about 286,000 kindergartners starting school without a documented MMR series.

What was said at confirmation

KFF Health News, in a report headlined "RFK Jr. Made Promises in Order To Become Health Secretary. He's Broken Many of Them.", records Health and Human Services Secretary Robert F. Kennedy Jr. saying: "Senator, I support vaccines. I support the childhood schedule. I will do that." The same report records the commitment as: "If confirmed, he will maintain the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices' recommendations without changes."

The fact sheet describes the new recommendation as a decrease from the 18 diseases it attributes to the CDC. Whether that decrease constitutes a formal change to the Advisory Committee on Immunization Practices' recommendations is not stated in either White House document reviewed for this piece.

Analysis

Read against the manufacturing record, the order's MMR provision directs the use of a product class that, on the sources assembled here, is not on the U.S. market. CIDRAP states no monovalent measles, mumps or rubella vaccine is available in the United States. The manufacturer that once made them said, in a record dated March 2012, that it would not resume production, and CIDRAP relays a more recent Merck estimate to PolitiFact of more than 10 years to approval and commercialization for split products. Neither record is a statement about 2026 policy; together they are the only evidence in these sources about who would make the three shots the order calls for, and neither describes a producer.

The second pairing is arithmetic. The claim at the signing was that children would receive 20% of what one combined shot delivers. The cited counter-record, from CIDRAP and echoed by Cassidy, is that a split leaves the antigen tally at six while raising the injection count from two to six. Those two statements appear in different sources and cannot both describe the same outcome.

A falsifiable test follows: on the record above, no monovalent measles, mumps or rubella vaccine will be licensed for sale in the United States by August 12, 2027. That is checkable on that date against the FDA's list of licensed biological products.